Pfizer Signs Up to $2.63 Billion Starna CAR-T Deal

Pfizer has signed an exclusive licensing agreement with Starna Therapeutics covering three early-stage CAR-T programs for autoimmune diseases, with $330 million upfront and up to $2.3 billion in milestone payments. Starna is also eligible for royalties on net sales of approved products, and the milestone payments are tied to development and commercial progress.

The agreement gives Pfizer exclusive rights outside Greater China to develop, manufacture and commercialize the three programs, all of which are at the pre-investigational new drug application stage. The programs use an in vivo approach to chimeric antigen receptor T-cell therapy, known as CAR-T, and come from Starna, a biotechnology company developing RNA medicines for use in the body.

Pfizer will lead clinical development outside Greater China and plans to use its U.S. facilities to manufacture the finished drug product for the initial clinical trials. Pfizer will also have sole control over commercialization outside Greater China for all products covered by the agreement.

Beyond the three autoimmune disease programs, Pfizer gains rights to use Starna’s in vivo CAR-T technology in inflammation and immunology as well as in oncology. The agreement also gives Pfizer options to take exclusive licenses on compounds created under a separate research collaboration, in addition to the rights it has already secured for the three programs. Pfizer can also opt to expand its territory to include exclusive development and commercialization rights in Greater China for each exclusively licensed compound and product.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!

Sign up now!

  • <<
  • >>

Join the Discussion